Evidence map›Paper›PMID 29191835›Full record

ArticleThe Journal of biological chemistry2018

Phosphorylation of human enhancer filamentation 1 (HEF1) stimulates interaction with Polo-like kinase 1 leading to HEF1 localization to focal adhesions.

Kyung Ho Lee, Jeong-Ah Hwang, Sun-Ok Kim, Jung Hee Kim, Sang Chul Shin, Eunice EunKyeong Kim, Kyung S Lee, Kunsoo Rhee, Byeong Hwa Jeon, Jeong Kyu Bang and 8 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Kyung Ho LeeFrom the World Class Institute, Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, 30 Yeongudanji-ro, Ochang, Cheongwon, Chungbuk 28116, Korea, leekh@kribb.re.kr.
Jeong-Ah HwangFrom the World Class Institute, Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, 30 Yeongudanji-ro, Ochang, Cheongwon, Chungbuk 28116, Korea.
Sun-Ok KimFrom the World Class Institute, Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, 30 Yeongudanji-ro, Ochang, Cheongwon, Chungbuk 28116, Korea.
Jung Hee Kimthe Biomedical Research Institute, Korea Institute of Science and Technology, Hwarangno 14-gil 5, Seongbuk-gu, Seoul 02792, Korea.
Sang Chul Shinthe Biomedical Research Institute, Korea Institute of Science and Technology, Hwarangno 14-gil 5, Seongbuk-gu, Seoul 02792, Korea.
Eunice EunKyeong Kimthe Biomedical Research Institute, Korea Institute of Science and Technology, Hwarangno 14-gil 5, Seongbuk-gu, Seoul 02792, Korea.
Kyung S Leethe Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892.
Kunsoo Rheethe Department of Biological Sciences, Seoul National University, Seoul 08826, Korea.
Byeong Hwa Jeonthe Research Institute of Medical Sciences, Department of Physiology, College of Medicine, Chungnam National University, Daejeon 35015, Korea.
Jeong Kyu Bangthe Division of Magnetic Resonance, Korea Basic Science Institute, Ochang 28119, Korea.
Hyunjoo Cha-MolstadFrom the World Class Institute, Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, 30 Yeongudanji-ro, Ochang, Cheongwon, Chungbuk 28116, Korea.
Nak-Kyun SoungFrom the World Class Institute, Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, 30 Yeongudanji-ro, Ochang, Cheongwon, Chungbuk 28116, Korea.
Jae-Hyuk JangFrom the World Class Institute, Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, 30 Yeongudanji-ro, Ochang, Cheongwon, Chungbuk 28116, Korea.
Sung-Kyun KoFrom the World Class Institute, Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, 30 Yeongudanji-ro, Ochang, Cheongwon, Chungbuk 28116, Korea.
Hee Gu Leethe Genome Structure Research Center, Korea Research Institute of Bioscience and Biotechnology, 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Korea, and.
Jong Seog AhnFrom the World Class Institute, Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, 30 Yeongudanji-ro, Ochang, Cheongwon, Chungbuk 28116, Korea.
Yong Tae Kwonthe Protein Metabolism Medical Research Center and Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul 03080, Korea yok5@snu.ac.kr.
Bo Yeon KimFrom the World Class Institute, Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, 30 Yeongudanji-ro, Ochang, Cheongwon, Chungbuk 28116, Korea, bykim@kribb.re.kr.
Korea Research Institute of Bioscience and Biotechnology · KRKorea Institute of Science and Technology · KRSeoul National University · KRCenter for Cancer Research · USChungnam National University · KRKorea Basic Science Institute · KR

Funding

Molecular basis of centriole duplicationZIABC011518 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LEE, KYUNG · 2013 to 2025
$11.2M
6 · The paper itself

Abstract

Elevated expression of human enhancer filamentation 1 (HEF1; also known as NEDD9 or Cas-L) is an essential stimulus for the metastatic process of various solid tumors. This process requires HEF1 localization to focal adhesions (FAs). Although the association of HEF1 with FAs is considered to play a role in cancer cell migration, the mechanism targeting HEF1 to FAs remains unclear. Moreover, up-regulation of Polo-like kinase 1 (Plk1) positively correlates with human cancer metastasis, yet how Plk1 deregulation promotes metastasis remains elusive. Here, we report that casein kinase 1δ (CK1δ) phosphorylates HEF1 at Ser-780 and Thr-804 and that these phosphorylation events promote a physical interaction between Plk1 and HEF1. We found that this interaction is critical for HEF1 translocation to FAs and for inducing migration of HeLa cells. Plk1-docking phosphoepitopes were mapped/confirmed in HEF1 by various methods, including X-ray crystallography, and mutated for functional analysis in HeLa cells. In summary, our results reveal the role of a phosphorylation-dependent HEF1-Plk1 complex in HEF1 translocation to FAs to induce cell migration. Our findings provide critical mechanistic insights into the HEF1-Plk1 complex-dependent localization of HEF1 to FAs underlying the metastatic process and may therefore contribute to the development of new cancer therapies.

Indexed as

Adaptor Proteins, Signal TransducingCell Cycle ProteinsCell LineCell ProliferationFocal AdhesionsHeLa CellsHumansImmunoblottingImmunoprecipitationPhosphoproteinsPhosphorylationPolo-Like Kinase 1Protein Serine-Threonine KinasesProto-Oncogene ProteinsAdaptor Proteins, Signal TransducingCell Cycle ProteinsNEDD9 protein, humanPhosphoproteinsPolo-Like Kinase 1Protein Serine-Threonine KinasesProto-Oncogene Proteinscell migrationfocal adhesionHEF1-Plk1 complexHEF1 pSer-780HEF1 pThr-804HEF1 translocationphosphorylationPlk1protein-protein interactionprotein targetingproton transportserine/threonine protein kinase

Identifiers

PMID29191835
PMCPMC5777258
OpenAlexW2775028544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.